# Capricor Therapeutics (CAPR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CAPR
## Company Profile
- Ticker: CAPR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Exosomes, Rare Disease
## Stock Data
- Close: 3.93 USD
- Market cap: 1583311154.62 USD
- Last updated: 2026-08-05
## Business Overview
### Cell Therapy for Duchenne Muscular Dystrophy
Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy.
### Deramiocel
The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling.
### HOPE-3 Evidence
The Phase 3 HOPE-3 study met its primary upper-limb function endpoint and all type I error-controlled secondary endpoints.
## Why The Stock Is Moving

As of Aug 5, 2026, CAPR closed down 5.76% at $3.93. No new same-company headline was identified in the current news window.

## Future Catalysts

- The FDA PDUFA action date for the deramiocel BLA is August 22, 2026.
- FDA labeling discussions are expected during the active BLA review.

## Drug Assets

- deramiocel

## Recent News
- 2026-07-30 13:30 EST — [Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-provides-update-on-fda-advisory-committee-meeting-for-dera-ef1c36a3) — Source: Capricor Therapeutics
- 2026-07-29 14:05 EST — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) — Source: Capricor Therapeutics
- 2026-07-27 15:00 EST — [Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel](https://biopharmsignal.com/news/CAPR/capricor-comments-on-briefing-materials-ahead-of-july-29-fda-advisory-committee--3a3054d7) — Source: Capricor Therapeutics
- 2026-06-26 14:02 EST — [Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-fda-advisory-committee-meeting-to-review-bla-for-4de22ae1) — Source: Capricor Therapeutics
- 2026-06-26 13:05 EST — [Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference](https://biopharmsignal.com/news/CAPR/capricor-to-present-positive-five-year-hope-2-ole-data-and-hope-3-phase-3-result-4fe04208) — Source: Capricor Therapeutics